<DOC>
	<DOCNO>NCT01098760</DOCNO>
	<brief_summary>This single-arm , open-label post-authorization study evaluate safety efficacy profile sorafenib evaluate Child-Pugh status progression subject advance HCC treat sorafenib Taiwan . In subgroup patient ( hand-foot skin reaction ( HFSR ) study subgroup ) , study also aim test topical corticosteroid preventive counter-measure apply hand foot first 3 week sorafenib treatment reduce incidence severity HFSR compare matching , corticosteroid-free cosmetic ointment , measure first 3 6 week sorafenib treatment .</brief_summary>
	<brief_title>Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial Taiwanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically document HCC ( documentation original biopsy diagnosis acceptable tumor tissue unavailable ) clinical diagnosis American Association Study Liver Disease ( AASLD ) criterion cirrhotic patient require . For subject without cirrhosis , histological cytological confirmation mandatory . Unresectable advanced/or metastatic HCC amenable local treatment modality Patients must least one tumor lesion meet follow criterion : 1 . The lesion accurately measure least one dimension accord RECIST amendment ( version 1.0 ) 2 . The lesion previously treat local therapy ( surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation ) . Patients receive local therapy surgery , radiation therapy , hepatic arterial embolization , chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation eligible . Previously treat lesion select target lesion . Local therapy must complete least 4 week prior baseline scan . Cirrhotic status ChildPugh Class A. ChildPugh status calculate base clinical finding laboratory result screen period . Male female patient &gt; /= 18 year age Patients life expectancy least 12 week Patients Eastern Cooperative Oncology Group ( ECOG ) performance score ( PS ) 0,1 2 Resolution acute toxic effect prior local treatment National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 grade &lt; /= 1 The following laboratory parameter : 1 . Platelet count &gt; /= 60 x 10^9/L 2 . Hemoglobin &gt; /= 8.5 g/dL 3 . Total bilirubin &lt; /= 2.8 mg/dL 4 . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; /= 5 x upper limit normal 5 . Serum creatinine &lt; /= 1.5 x upper limit normal 6 . Prothrombin timeinternational normalize ratio ( INR ) &lt; /=2.3 PT &lt; /= 6 second control . Patients therapeutically anticoagulated agent warfarin heparin allow participate provide prior evidence underlie abnormality parameter exist . Close monitoring least weekly evaluation perform INR stable base measurement pre dose , define local standard care . Previous concurrent cancer distinct primary site histology HCC , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit . Renal failure require hemo peritoneal dialysis . History cardiac disease : Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 Active coronary artery disease ( myocardial infarction 6 month prior study entry permit ) Cardiac arrhythmia require antiarrhythmic therapy Î²blockers digoxin ) Uncontrolled hypertension , define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical management . Active , clinically serious infection ( &gt; grade 2 NCICTCAE , version 4.0 ) , except HBV/HCV infection Known history human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness serious acute chronic illness Known central nervous system tumor , include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry History organ allograft ChildPugh Class B C Previous treatment yttrium90 spheres Clinically significant ( ie , symptomatic ) peripheral vascular disease Substance abuse medical , psychological , social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Patients unable take oral medication , require intravenous alimentation , malabsorption syndrome condition affect gastrointestinal absorption , active peptic ulcer disease Any condition unstable could jeopardize safety patient his/her compliance study Pregnant breastfeeding patient . Women childbearing potential must negative urine pregnancy test perform within 7 day prior start study drug ( assess locally ) . Both men woman enrol trial must use adequate barrier birth control measure course trial . Uncontrolled ascites ( define easily control diuretic treatment ) Patients viral disease ( eg , varicella , herpes zoster ) ; tuberculous syphilitic process area treat ; hypersensitivity active substance excipients include HFSR study subgroup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hepatocellular Carcinoma ( HCC )</keyword>
</DOC>